Fractyl Health Sees 420.59% Surge in Search Activity

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:Fractyl Health, 420.59% surge in interestPipeline and key clinical candidates for these companies:Fractyl Healthis a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl's goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease.Recent news on these stocks:January 30BofA lowered the firm's price target on Fractyl Health to $2 from $5 and keeps a Buy rating on the shares after the company provided new, six-month randomized controlled data of its Revita procedure in weight maintenance post-discontinuation of a GLP1 therapy. The "data were not perfect," but the firm thinks the pivotal results should benefit from a much larger sample size and optimization of trial execution, says the analyst, who lowered the firm's sales forecast pending clarity on the profile strength based on additional data.January 29Fractyl Health announced positive six-month randomized results from the ongoing REMAIN-1 Midpoint Cohort, a blinded, sham-controlled study evaluating Revita for weight maintenance following GLP-1 drug discontinuation. Across the prespecified efficacy population, Revita-treated patients experienced a 4.5% weight regain vs 7.5% in the sham arm at 6 months, consistent with meaningful and sustained attenuation of the expected post-GLP-1 rebound trajectory. An exploratory analysis of patients who achieved above median weight loss during GLP-1 run-in showed that Revita-treated participants experienced 4.2% weight regain versus 13.3% with sham at 6 months, corresponding to an approximately 70% relative reduction in post-GLP-1 weight regain. Revita-treated patients demonstrated improvements in cardiometabolic lipid parameters versus sham at 6 months, including increased HDL cholesterol and reduced triglyceride-to-HDL ratio, suggesting improved metabolic regulation following GLP-1 discontinuation. Revita continued to demonstrate favorable safety and tolerability results through six months, with no treatment-emergent serious adverse events related to the device or procedure, and no study discontinuations due to adverse events. No new related adverse events were observed between 3- and 6-month follow up.Morgan Stanley downgraded Fractyl Health to Equal Weight from Overweight with a price target of $2, down from $8. In the randomized REMAIN-1 midpoint cohort at six months, Revita patients experienced 4.5% weight regain, which fell short of expectations and raises questions, the analyst tells investors. While the firm continues to believe success in the pivotal study is possible, it is taking a more cautious view and moving to the sidelines.Hear more from InvestingChannel by signing up for.About "Biotech Alert"The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel's online financial news media ecosystem.This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.